Probiotic-guided CAR-T cells for solid tumor targeting

Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

(2023) Jason J. Luke et al.   CLINICAL CANCER RESEARCH

Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity

(2023) Thomas M. Savage et al.   Science Advances

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

(2023) Angela Q. Zhang et al.   Nature Biomedical Engineering

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

(2022) Louai Labanieh et al.   CELL

A programmable encapsulation system improves delivery of therapeutic bacteria in mice

(2022) Tetsuhiro Harimoto et al.   NATURE BIOTECHNOLOGY

CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers

(2022) Chuan Jin et al.   Nature Biomedical Engineering

Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity

(2021) John P. Murad et al.   MOLECULAR THERAPY

The microbiome and human cancer

(2021) Gregory D. Sepich-Poore et al.   SCIENCE

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

(2021) Stefanie Lesch et al.   Nature Biomedical Engineering

Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control

(2021) Ian C. Miller et al.   Nature Biomedical Engineering

Enhancing the tropism of bacteria via genetically programmed biosensors

(2021) Tiffany Chien et al.   Nature Biomedical Engineering

Engineering CAR-T cells to activate small-molecule drugs in situ

(2021) Thomas J. Gardner et al.   Nature Chemical Biology

Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies

(2020) Candice R. Gurbatri et al.   Science Translational Medicine

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

(2020) Deborah Nejman et al.   SCIENCE

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

(2020) Daniel S. Leventhal et al.   Nature Communications

A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers

(2020) Thomas J. Gniadek et al.   JOURNAL OF IMMUNOTHERAPY

Thermal Control of Engineered T-cells

(2020) Mohamad H. Abedi et al.   ACS Synthetic Biology

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

(2020) Kevin R. Parker et al.   CELL

Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

(2020) Anthony K. Park et al.   Science Translational Medicine

Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer

(2020) Lance B. Augustin et al.   JOURNAL OF DRUG TARGETING

DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation

(2020) Xiao Huang et al.   Nature Nanotechnology

Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin

(2020) Jessica Wagner et al.   Cancer Immunology Research

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

(2019) Bryan D. Choi et al.   NATURE BIOTECHNOLOGY

Programmable bacteria induce durable tumor regression and systemic antitumor immunity

(2019) Sreyan Chowdhury et al.   NATURE MEDICINE

Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy

(2019) Noor Momin et al.   Science Translational Medicine

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

(2018) Nan Chen et al.   CURRENT OPINION IN IMMUNOLOGY

Rewiring T-cell responses to soluble factors with chimeric antigen receptors

(2018) ZeNan L Chang et al.   Nature Chemical Biology

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity

(2018) A. J. Davenport et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

(2018) Sujita Sukumaran et al.   Cancer Discovery

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

(2018) Anna Wing et al.   Cancer Immunology Research

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

(2018) Manja Idorn et al.   OncoImmunology

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

(2017) Jun Ishihara et al.   Science Translational Medicine

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Two-step enhanced cancer immunotherapy with engineeredSalmonella typhimuriumsecreting heterologous flagellin

(2017) Jin Hai Zheng et al.   Science Translational Medicine

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

(2017) Melinda Mata et al.   Cancer Discovery

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

(2017) Sarah A. Richman et al.   Cancer Immunology Research

Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity

(2017) Spencer Park et al.   Scientific Reports

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

(2016) Cheng Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

(2016) Kole T. Roybal et al.   CELL

Synchronized cycles of bacterial lysis for in vivo delivery

(2016) M. Omar Din et al.   NATURE

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

(2016) E. Zah et al.   Cancer Immunology Research

TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity

(2015) D. Geng et al.   CANCER RESEARCH

Programmable probiotics for detection of cancer in urine

(2015) Tal Danino et al.   Science Translational Medicine

A Suite of Engineered GFP Molecules for Oligomeric Scaffolding

(2015) David J. Leibly et al.   STRUCTURE

Microbiota of Human Breast Tissue

(2014) Camilla Urbaniak et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Characterization of camel nanobodies specific for superfolder GFP fusion proteins

(2014) Aya Twair et al.   MOLECULAR BIOLOGY REPORTS

ICAM-1 as a molecular target for triple negative breast cancer

(2014) P. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing

(2014) M. M. Martino et al.   SCIENCE

Modulating the innate immune response by combinatorial engineering of endotoxin

(2013) Brittany D. Needham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY